APO RESEARCH · REPORT
Intravenous Immunoglobulin (IVIg)
Intravenous Immunoglobulin, also called gamma globulin or antibodies, is a highly purified blood product preparation that is derived from large pools of plasma donors. Plasma from approximately 1,000 to 10,000 persons is present in each unit or “lot” of Intravenous Immunoglobulin.
Product & engineering
Understand the product.
Intravenous Immunoglobulin, also called gamma globulin or antibodies, is a highly purified blood product preparation that is derived from large pools of plasma donors. Plasma from approximately 1,000 to 10,000 persons is present in each unit or “lot” of Intravenous Immunoglobulin.
Selected research
Industry Research
Intravenous Immunoglobulin (IVIg) Industry Research Report 2026
Market perspective
Intravenous Immunoglobulin, also called gamma globulin or antibodies, is a highly purified blood product preparation that is derived from large pools of plasma donors. Plasma from approximately 1,000 to 10,000 persons is present in each unit or “lot” of Intravenous Immunoglobulin.
Global Intravenous Immunoglobulin (IVIg) main players are Baxter, Grifols, CSL, Octapharma, etc. Global top four manufacturers hold a share above 65%. North America is the largest market, with a share about 45%.
Report Scope
Read the full market overview
This report quantifies the global Intravenous Immunoglobulin (IVIg) market in terms of revenue (US$ million) and, where applicable, sales volume (K Bottle), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Bottle) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Intravenous Immunoglobulin (IVIg) Market by Company
Baxter
Grifols
CSL
Octapharma
Biotest
Kedrion
Hualan Bio
CNBG
Shanghai RAAS
CBPO
LFB Group
BPL
Sichuan Yuanda Shuyang
Intravenous Immunoglobulin (IVIg) Segment by Type
IVIg Liquid
IVIg Powder
Intravenous Immunoglobulin (IVIg) Segment by Application
Immunodeficiency
Autoimmune Disease
Acute Infection
Intravenous Immunoglobulin (IVIg) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intravenous Immunoglobulin (IVIg) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Intravenous Immunoglobulin (IVIg) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intravenous Immunoglobulin (IVIg).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Intravenous Immunoglobulin (IVIg) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Intravenous Immunoglobulin (IVIg) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Intravenous Immunoglobulin (IVIg) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- IVIg Liquid
- IVIg Powder
Applications
- Immunodeficiency
- Autoimmune Disease
- Acute Infection
Companies covered
- Baxter
- Grifols
- CSL
- Octapharma
- Biotest
- Kedrion
- Hualan Bio
- CNBG
- Shanghai RAAS
- CBPO
- LFB Group
- BPL
- Sichuan Yuanda Shuyang
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Intravenous Immunoglobulin (IVIg) Market Size (2021-2032)
- 2.2.2 Global Intravenous Immunoglobulin (IVIg) Sales (2021-2032)
- 2.2.3 Global Intravenous Immunoglobulin (IVIg) Market Average Price (2021-2032)
- 2.3 Intravenous Immunoglobulin (IVIg) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 IVIg Liquid
- 2.3.3 IVIg Powder
- 2.4 Intravenous Immunoglobulin (IVIg) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Immunodeficiency
- 2.4.3 Autoimmune Disease
- 2.4.4 Acute Infection
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Intravenous Immunoglobulin (IVIg) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Intravenous Immunoglobulin (IVIg) Sales (K Bottle) of Manufacturers (2021-2026)
- 3.3 Global Intravenous Immunoglobulin (IVIg) Revenue of Manufacturers (2021-2026)
- 3.4 Global Intravenous Immunoglobulin (IVIg) Average Price by Manufacturers (2021-2026)
- 3.5 Global Intravenous Immunoglobulin (IVIg) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Intravenous Immunoglobulin (IVIg), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Intravenous Immunoglobulin (IVIg), Product Type & Application
- 3.8 Global Manufacturers of Intravenous Immunoglobulin (IVIg), Established Date
- 3.9 Global Intravenous Immunoglobulin (IVIg) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Baxter
- 4.1.1 Baxter Company Information
- 4.1.2 Baxter Business Overview
- 4.1.3 Baxter Intravenous Immunoglobulin (IVIg) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Baxter Intravenous Immunoglobulin (IVIg) Product Portfolio
- 4.1.5 Baxter Recent Developments
- 4.2 Grifols
- 4.2.1 Grifols Company Information
- 4.2.2 Grifols Business Overview
- 4.2.3 Grifols Intravenous Immunoglobulin (IVIg) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Grifols Intravenous Immunoglobulin (IVIg) Product Portfolio
- 4.2.5 Grifols Recent Developments
- 4.3 CSL
- 4.3.1 CSL Company Information
- 4.3.2 CSL Business Overview
- 4.3.3 CSL Intravenous Immunoglobulin (IVIg) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 CSL Intravenous Immunoglobulin (IVIg) Product Portfolio
- 4.3.5 CSL Recent Developments
- 4.4 Octapharma
- 4.4.1 Octapharma Company Information
- 4.4.2 Octapharma Business Overview
- 4.4.3 Octapharma Intravenous Immunoglobulin (IVIg) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Octapharma Intravenous Immunoglobulin (IVIg) Product Portfolio
- 4.4.5 Octapharma Recent Developments
- 4.5 Biotest
- 4.5.1 Biotest Company Information
- 4.5.2 Biotest Business Overview
- 4.5.3 Biotest Intravenous Immunoglobulin (IVIg) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Biotest Intravenous Immunoglobulin (IVIg) Product Portfolio
- 4.5.5 Biotest Recent Developments
- 4.6 Kedrion
- 4.6.1 Kedrion Company Information
- 4.6.2 Kedrion Business Overview
- 4.6.3 Kedrion Intravenous Immunoglobulin (IVIg) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Kedrion Intravenous Immunoglobulin (IVIg) Product Portfolio
- 4.6.5 Kedrion Recent Developments
- 4.7 Hualan Bio
- 4.7.1 Hualan Bio Company Information
- 4.7.2 Hualan Bio Business Overview
- 4.7.3 Hualan Bio Intravenous Immunoglobulin (IVIg) Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Hualan Bio Intravenous Immunoglobulin (IVIg) Product Portfolio
- 4.7.5 Hualan Bio Recent Developments
- 4.8 CNBG
- 4.8.1 CNBG Company Information
- 4.8.2 CNBG Business Overview
- 4.8.3 CNBG Intravenous Immunoglobulin (IVIg) Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 CNBG Intravenous Immunoglobulin (IVIg) Product Portfolio
- 4.8.5 CNBG Recent Developments
- 4.9 Shanghai RAAS
- 4.9.1 Shanghai RAAS Company Information
- 4.9.2 Shanghai RAAS Business Overview
- 4.9.3 Shanghai RAAS Intravenous Immunoglobulin (IVIg) Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Shanghai RAAS Intravenous Immunoglobulin (IVIg) Product Portfolio
- 4.9.5 Shanghai RAAS Recent Developments
- 4.10 CBPO
- 4.10.1 CBPO Company Information
- 4.10.2 CBPO Business Overview
- 4.10.3 CBPO Intravenous Immunoglobulin (IVIg) Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 CBPO Intravenous Immunoglobulin (IVIg) Product Portfolio
- 4.10.5 CBPO Recent Developments
- 4.11 LFB Group
- 4.11.1 LFB Group Company Information
- 4.11.2 LFB Group Business Overview
- 4.11.3 LFB Group Intravenous Immunoglobulin (IVIg) Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 LFB Group Intravenous Immunoglobulin (IVIg) Product Portfolio
- 4.11.5 LFB Group Recent Developments
- 4.12 BPL
- 4.12.1 BPL Company Information
- 4.12.2 BPL Business Overview
- 4.12.3 BPL Intravenous Immunoglobulin (IVIg) Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 BPL Intravenous Immunoglobulin (IVIg) Product Portfolio
- 4.12.5 BPL Recent Developments
- 4.13 Sichuan Yuanda Shuyang
- 4.13.1 Sichuan Yuanda Shuyang Company Information
- 4.13.2 Sichuan Yuanda Shuyang Business Overview
- 4.13.3 Sichuan Yuanda Shuyang Intravenous Immunoglobulin (IVIg) Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Sichuan Yuanda Shuyang Intravenous Immunoglobulin (IVIg) Product Portfolio
- 4.13.5 Sichuan Yuanda Shuyang Recent Developments
5 Global Intravenous Immunoglobulin (IVIg) Market Scenario by Region
- 5.1 Global Intravenous Immunoglobulin (IVIg) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Intravenous Immunoglobulin (IVIg) Sales by Region: 2021-2032
- 5.2.1 Global Intravenous Immunoglobulin (IVIg) Sales by Region: 2021-2026
- 5.2.2 Global Intravenous Immunoglobulin (IVIg) Sales by Region: 2027-2032
- 5.3 Global Intravenous Immunoglobulin (IVIg) Revenue by Region: 2021-2032
- 5.3.1 Global Intravenous Immunoglobulin (IVIg) Revenue by Region: 2021-2026
- 5.3.2 Global Intravenous Immunoglobulin (IVIg) Revenue by Region: 2027-2032
- 5.4 North America Intravenous Immunoglobulin (IVIg) Market Facts & Figures by Country
- 5.4.1 North America Intravenous Immunoglobulin (IVIg) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Intravenous Immunoglobulin (IVIg) Sales by Country (2021-2032)
- 5.4.3 North America Intravenous Immunoglobulin (IVIg) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Intravenous Immunoglobulin (IVIg) Market Facts & Figures by Country
- 5.5.1 Europe Intravenous Immunoglobulin (IVIg) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Intravenous Immunoglobulin (IVIg) Sales by Country (2021-2032)
- 5.5.3 Europe Intravenous Immunoglobulin (IVIg) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Intravenous Immunoglobulin (IVIg) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Intravenous Immunoglobulin (IVIg) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Intravenous Immunoglobulin (IVIg) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Intravenous Immunoglobulin (IVIg) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Intravenous Immunoglobulin (IVIg) Market Facts & Figures by Country
- 5.7.1 South America Intravenous Immunoglobulin (IVIg) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Intravenous Immunoglobulin (IVIg) Sales by Country (2021-2032)
- 5.7.3 South America Intravenous Immunoglobulin (IVIg) Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Intravenous Immunoglobulin (IVIg) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Intravenous Immunoglobulin (IVIg) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Intravenous Immunoglobulin (IVIg) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Intravenous Immunoglobulin (IVIg) Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Intravenous Immunoglobulin (IVIg) Sales by Type (2021-2032)
- 6.1.1 Global Intravenous Immunoglobulin (IVIg) Sales by Type (2021-2032) & (K Bottle)
- 6.1.2 Global Intravenous Immunoglobulin (IVIg) Sales Market Share by Type (2021-2032)
- 6.2 Global Intravenous Immunoglobulin (IVIg) Revenue by Type (2021-2032)
- 6.2.1 Global Intravenous Immunoglobulin (IVIg) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Intravenous Immunoglobulin (IVIg) Revenue Market Share by Type (2021-2032)
- 6.3 Global Intravenous Immunoglobulin (IVIg) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Intravenous Immunoglobulin (IVIg) Sales by Application (2021-2032)
- 7.1.1 Global Intravenous Immunoglobulin (IVIg) Sales by Application (2021-2032) & (K Bottle)
- 7.1.2 Global Intravenous Immunoglobulin (IVIg) Sales Market Share by Application (2021-2032)
- 7.2 Global Intravenous Immunoglobulin (IVIg) Revenue by Application (2021-2032)
- 7.2.1 Global Intravenous Immunoglobulin (IVIg) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Intravenous Immunoglobulin (IVIg) Revenue Market Share by Application (2021-2032)
- 7.3 Global Intravenous Immunoglobulin (IVIg) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Intravenous Immunoglobulin (IVIg) Value Chain Analysis
- 8.1.1 Intravenous Immunoglobulin (IVIg) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Intravenous Immunoglobulin (IVIg) Production Mode & Process
- 8.2 Intravenous Immunoglobulin (IVIg) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Intravenous Immunoglobulin (IVIg) Distributors
- 8.2.3 Intravenous Immunoglobulin (IVIg) Customers
9 Global Intravenous Immunoglobulin (IVIg) Analyzing Market Dynamics
- 9.1 Intravenous Immunoglobulin (IVIg) Industry Trends
- 9.2 Intravenous Immunoglobulin (IVIg) Industry Drivers
- 9.3 Intravenous Immunoglobulin (IVIg) Industry Opportunities and Challenges
- 9.4 Intravenous Immunoglobulin (IVIg) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst